Biohaven completes enrollment in late-stage troriluzole anxiety disorder study

Biohaven Pharmaceuticals (BHVN +1.8%) completes enrollment in a Phase 3 clinical trial evaluating troriluzole in patients with generalized anxiety disorder (GAD).

The primary endpoint is the change from baseline to week 8 in a GAD scale called HAM-A compared to placebo. Topline data should be available later this quarter.

The company says troriluzole is a third-generation prodrug that modulates an excitatory neurotransmitter called glutamate by reducing its levels at nerve synapses.

https://seekingalpha.com/news/3510232-biohaven-completes-enrollment-late-stage-study-troriluzole-anxiety-disorder